Clover Health (CLOV) Q2 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q2 2026 Medicare Advantage membership growth of 48% YoY to 157,309 members and total revenue of $743.2M (+55.6% YoY). GAAP net income turned positive at $28M (an improvement of $39M YoY), and non-GAAP adjusted EBITDA rose 139.2% YoY to $40.9M, helped by gross profit of $153M (+53.6%) and an 80bps improvement in BER to 87.6%. The company raised FY2026 guidance across key metrics—revenue to $2.92B–$3.0B (from $2.81B–$2.92B) and adjusted EBITDA to $70M–$85M (from $50M–$70M)—citing cohort maturation under its AI-driven Clover Assistant and favorable medical cost trend development, with 4.5-star CMS payment-year rating maintained amid an appeal.

Analysis

CLOV is shifting from a “story stock” to a cohort-math stock: the near-term upside is less about AI branding and more about whether the newer member books keep aging into better unit economics fast enough to offset acquisition spend. The market will likely reward the raised guide immediately, but the more durable re-rating comes only if Q3/Q4 claims trends stay contained and AEP doesn’t force a step-up in sales expense that eats the operating leverage.

The second-order winner is regional MA disruption, not just CLOV. If large nationals continue rationalizing markets, smaller incumbents in New Jersey/Georgia lose the ability to underprice aggressively without sacrificing margin; that should support CLOV share gain and potentially pressure peers with weaker local density. The flip side is that this same dynamic can disappear quickly if competitors re-enter with sharper bids, so the 2027 setup is more fragile than management’s tone implies.

The biggest bear case is that the market is over-indexing on the star-rating headline while underweighting the fact that the real earnings driver is still medical-cost behavior in relatively young cohorts. CMS appeal risk is a months-not-days catalyst, but outpatient utilization and dental/Part D noise can reverse the trend over 1-2 quarters. If 2027 bids prove more concessionary than expected, the stock could give back a meaningful portion of the rerate even with continued membership growth.

Key Decisions for Investors

• Long CLOV on a post-earnings pullback, with a 3-6 month horizon into AEP/plan-preview updates; thesis is that the market will continue to pay for visible cohort maturation and self-funded growth. Falsifier: any Q3 commentary showing outpatient trend re-acceleration or a 2026 cohort that stops improving year-over-year.
• Use a pair trade: long CLOV / short HUM or a managed-care basket (e.g., XLV proxy) for 1-3 months to isolate idiosyncratic cohort and rating upside while hedging sector beta. Risk: if CMS appeal noise hits Clover specifically, the pair can underperform even if the sector is weak.
• If options liquidity permits, consider a 6-9 month call spread in CLOV rather than outright common to express upside into 2027 bid setup while capping downside from an appeal reversal. Best entry is after the initial post-print move fades, not on the first gap higher.
• Set a watch item on CMS appeal milestones and 2027 bid commentary; if the rating benefit is reversed or diluted, reduce exposure immediately. The stock’s multiple is likely much more sensitive to that binary than to incremental quarterly EBITDA beats.